Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular Age-Related Macular Degeneration

What this Trial Is About

Researchers are evaluating two approaches for managing neovascular age-related macular degeneration nAMD to find out if home optical coherence tomography OCT-guided treatment improves visual outcomes or reduces the number of injections compared to the common Treat and Extend dosing method. The study addresses the current challenge of determining the optimal number of anti-vascular endothelial growth factor anti-VEGF injections needed for each patient, aiming to reduce treatment burden and costs by allowing more personalized care through daily monitoring with home OCT. Participants will receive intravitreal injections of 6 mg faricimab and be randomly assigned to either the Treat and Extend group or the Home OCT-guided treatment group. The Treat and Extend group will have office visits every 4 to 18 weeks for vision testing and imaging, while the Home OCT group will perform daily self-scans at home and only return for visits when disease activity is detected by the home device. The study includes a baseline phase with initial injection and imaging confirmation before randomization, followed by 104 weeks of treatment and monitoring. During the study, participants will undergo vision tests, eye exams, and various imaging procedures at scheduled visits or as triggered by home OCT scans. Researchers will track changes in visual acuity and count the number of injections over two years. Close monitoring ensures scan quality and disease status before randomization. The study measures include the change in visual acuity letter score and total injections received, aiming to compare the effectiveness and treatment burden between the two methods over 104 weeks.

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD